GTN and Nitrates in CABG Patients for Angina Management

Acute Angina Management

The American College of Cardiology recommends that patients with prior CABG who develop angina should be treated with sublingual nitroglycerin for acute symptom relief, with careful attention to hemodynamic stability and avoidance of tolerance through intermittent dosing regimens 1, 2
Do not administer sublingual nitroglycerin if systolic blood pressure is <90 mmHg or ≥30 mmHg below baseline, as recommended by the American College of Cardiology 1, 2
Avoid administering sublingual nitroglycerin to patients with marked bradycardia or tachycardia, as recommended by the American College of Cardiology 1, 2
The American College of Cardiology absolutely contraindicates the use of sublingual nitroglycerin if phosphodiesterase-5 inhibitors have been used within a certain time frame, as this combination can cause profound hypotension, MI, or death 2

For post-CABG patients with recurrent unstable angina requiring hospitalization, the American College of Cardiology recommends starting IV nitroglycerin at 10 mcg/min, increasing by 10 mcg/min every 3-5 minutes until symptom relief or blood pressure response occurs 1, 2
The American College of Cardiology recommends not titrating systolic BP below 110 mmHg in normotensive patients or >25% below baseline mean arterial pressure in hypertensive patients 1, 2
A practical ceiling dose of IV nitroglycerin is 200 mcg/min, though higher doses have been used safely for prolonged periods, as recommended by the American College of Cardiology 1, 2
The American College of Cardiology recommends converting to oral/topical nitrates within 24 hours once symptoms are controlled for 12-24 hours to avoid tolerance and unnecessary IV therapy 1, 2

In patients requiring repeat CABG or other surgery, prophylactic intraoperative nitroglycerin has uncertain benefit and may cause cardiovascular decompensation through preload reduction, according to Circulation 3
The American College of Cardiology recommends that nitroglycerin should only be used intraoperatively when hemodynamic effects of concurrent anesthetics and intravascular volume status are carefully considered 3
Recurrent angina after CABG may indicate graft failure, native vessel progression, or incomplete revascularization, as reported in Circulation 4

The American College of Cardiology recommends not continuing IV nitroglycerin in patients free of ischemic symptoms, as this promotes tolerance without benefit 1, 2
The American College of Cardiology recommends avoiding abrupt cessation of IV nitroglycerin, which can cause rebound ischemia; instead, taper gradually 1

Nitroglycerin acts primarily as a vasodilator that reduces cardiac preload and afterload while dilating coronary arteries, as indicated by the American College of Cardiology, and is specifically indicated for cardiac conditions, particularly for relief of angina pectoris due to coronary artery disease 5, 6, 7
The American College of Cardiology suggests that nitroglycerin works through venodilation and arterial dilation effects, which are primarily beneficial for cardiac-related conditions 8, 9

Inappropriate use of nitroglycerin for non-cardiac pain can lead to significant hypotension and cardiovascular decompensation, according to the American Heart Association 5, 6
The American College of Cardiology warns that the venodilating and arterial dilating effects of nitroglycerin can be potentiated by other medications, leading to dangerous drops in blood pressure 8, 10
The American Heart Association notes that prophylactic use of nitroglycerin in patients at high risk may have no effects or may actually lead to cardiovascular decompensation through decreases in preload 9, 11

The American College of Cardiology recommends that nitroglycerin should be used only when the hemodynamic effects of other agents being used and intravascular volume status have been considered 6, 10
The American Heart Association advises that relief with nitroglycerin is not necessarily diagnostic of myocardial ischemia and should not be used as a diagnostic criterion, with a strength of evidence rated as high 12
Inadvertent systemic hypotension with resulting worsening of myocardial ischemia is the most serious potential complication of nitroglycerin therapy, as warned by the American College of Cardiology 8, 12

The American College of Cardiology cautions against assuming that pain relief after nitroglycerin administration indicates cardiac etiology, as this approach has poor specificity 12
The American Heart Association recommends against using nitroglycerin as a diagnostic test to differentiate cardiac from non-cardiac pain, due to its poor specificity 12
The American College of Cardiology advises against administering nitroglycerin without monitoring for hypotension, which is the most serious potential complication, with a strength of evidence rated as high 12
Failing to consider contraindications such as hypotension, marked bradycardia or tachycardia with relative hypotension, or recent use of phosphodiesterase inhibitors is a common pitfall to avoid, as warned by the American College of Cardiology 12